XML 39 R28.htm IDEA: XBRL DOCUMENT
v3.22.1

NIH Contract (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2022
Research and Development [Abstract] |
Summary of Research and Development Activity Under NIH Contract | The following table summarizes the activity under the NIH Contract as of March 31, 2022 and December 31, 2021 (in thousands):
|  | March 31, 2022 |  | December 31, 2021
Cash receipts from milestones achieved |  | $ | 34,016 |  |  | $ | 34,016 |
Cumulative amounts applied against operating costs (excluding depreciation) |  | (4,526) |  |  | (4,522) |
Cumulative amounts applied against depreciation expense for assets placed in service |  | (1,510) |  |  | (703) |
Cumulative amounts recognized as non-operating income |  | (7,140) |  |  | (7,140) |
Total deferred grant income |  | $ | 20,840 |  |  | $ | 21,651 |
Assets placed in service, gross |  | $ | 20,425 |  |  | $ | 16,890 |
Construction-in-progress |  | 937 |  |  | 3,909 |
Cumulative amounts applied against depreciation expense |  | (1,510) |  |  | (703) |
Carrying value of property and equipment, net |  | 19,852 |  | 20,096
Estimated future capital expenditures |  | 988 |  |  | 1,555 |
Total deferred grant income |  | $ | 20,840 |  |  | $ | 21,651 |
Deferred grant income, current |  | $ | 3,603 |  |  | $ | 3,535 |
Deferred grant income, non-current |  | 17,237 |  |  | 18,116 |
Total deferred grant income |  | $ | 20,840 |  |  | $ | 21,651 |

X
- References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration